Research programme: Dicer-substrate siRNA therapeutics - Dicerna

Drug Profile

Research programme: Dicer-substrate siRNA therapeutics - Dicerna

Alternative Names: CTNNB1 DsiRNA; DCR BCAT; DCR-HBV; DCR-PHXC; Dicer siRNA - Dicerna; DsiRNA - Dicerna; DsiRNA-EX conjugate - Dicerna; GalNAc-DsiRNA-EX conjugates; GalXC therapy

Latest Information Update: 26 Apr 2017

Price : $50

At a glance

  • Originator Dicerna Pharmaceuticals
  • Class Small interfering RNA
  • Mechanism of Action Glycolate oxidase expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies; Hepatitis B; Hypercholesterolaemia; Primary hyperoxaluria; Solid tumours
  • Research Liver disorders
  • Discontinued Hepatitis C; Hyperlipidaemia; Rheumatoid arthritis; Type 2 diabetes mellitus

Most Recent Events

  • 08 May 2017 Dicerna announces intention to submit IND or CTA for Hepatitis B in the final quarter of 2018
  • 26 Apr 2017 Dicerna pharmaceuticals plans to initiate clinical trials of five programmes
  • 30 Mar 2017 Dicerna announces intention to submit IND to the US FDA for a rare liver disease in 2Q 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top